Pharma & Biotech Global Week in Review 5 May 2010 from IP Think Tank

Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/

 
Highlights this week included:

Valcyte (Valgancyclovir) – India: Roche loses Valcyte case (Spicy IP) (Generic Pharmaceuticals and IP)

Viagra (Sildenafil) – Brazil patents to expire 1 year early? – Supreme Court of Justice decision on Viagra patent (IPKat) (IP tango)

Further developments on double patenting at the EPO – T1423/07 Cyclic Amine derivative/BOEHRINGER INGELHEIM VETMEDICA GmbH (IPKat) (EPLAW)

 
General

BIO announces new policy on options for increasing access to medicines in the developing world (Patently BIOtech)

BIO2010 Day 1 & 2: Getting Settled & Meetings & Measuring Biotechnology Innovation  (Biotech Blog) (Biotech Blog) (Biotech Blog)

China: Protecting pharmaceutical intellectual property rights in China (China Law Insight)

EU-India trade talks resume under cloud of concern for public health (IP Watch)

EU: Further developments on double patenting at the EPO – T1423/07 Cyclic Amine derivative/BOEHRINGER INGELHEIM VETMEDICA GmbH (IPKat) (EPLAW)

EU: Comments on the opinion of Advocate General Mengozzi in case C-428/08 Monsanto v Cefetra & Ors (EPLAW)

India: Article 300A of the Constitution: A constitutional right to ‘data exclusivity’? (Spicy IP)

Mexico, pharma patents and linkage: compositions can benefit too (IP tango)

Uganda Trade Minister supports anti-counterfeit law, so long as generics aren’t impeded (Afro-IP)

US: USPTO Administrator Arti Rai responds to Patent Docs post on PTO white paper (Patent Docs)

US: Public Patent Foundation persuades USPTO to cancel WARF’s human embryonic stem cell patent as lacking inventive step (The IP Factor)

US: The impact of Wyeth on patent terms (Patently-O)

 
Products

Augmentin (Amoxicillin, Clavulanate) – South Africa: Augmenting the Augmentin patent? SmithKline Beecham plc & Anor v Sandoz AG & Anor (Afro-IP)

Cenestin (conjugated estrogens)– US: Patent infringement suit in response to Para IV challenge: Teva Women’s Health, Inc. v. Watson Laboratories, Inc. et al. (Patent Docs)

Cipro (Ciprofloxacin) -US: A new hope? Second Circuit invites further review in Cipro patent settlement case (FDA Law Blog)

Concerta (Methylphenidate) – US: CAFC affirms invalidity of Concerta patent for lack of enablement: ALZA Corp. v Andrz Pharms. (Orange Book Blog) (Patent Docs)

Crestor (Rosuvastatin) – US: AstraZeneca files 9 patent infringement suits against defendants including Teva, Sun, Sandoz, Par Pharma., Mylan, Glenmark, Cobalt, Aurobindo and Apotex  (Patent Docs) (GenericsWeb)

Cydectin (Moxidectin) – US: Federal Circuit sides with FDA and PTO in decision; Court rules that approval phase begins when administrative NADA is initially submitted (FDA Law Blog)

Effexor (Venlafaxine) – US: Patent infringement complaint filed in response to Para IV certification: Wyeth LLC v. Aurobindo Pharma Ltd. et al. (Patent Docs)

Fenoglide (Fenofibrate)– US:Patent infringement complaint filed in response to Para IV certification: Shionogi Pharma Inc. et al. v. Impax Laboratories Inc. (Patent Docs)

Intuniv (Guanfacine) – US: Shire files patent suit against Teva over its plans to market generic Intuniv (Patent Quality Review Blog) (Patent Docs)

Istodax (Romidepsin) – US: Patent infringement complaint filed in response to Para IV certification: Celgene Corp. v. Cyclacel Pharmaceuticals Inc. (Patent Docs)

Plavix (Clopidogrel) – Netherlands: District Court of The Hague finds Sanofi-Aventis’ patent invalid for lack of inventive step in proceedings brought by RatioPharm (EPLAW)

Rapamune (Sirolimus) – US: Patent infringement complaint following Paragraph IV certification: Pfizer Inc. et al. v. Watson Pharmaceuticals, Inc. et al. (Patent Docs) (GenericsWeb)

Trilipix (Fenofibrate) – US: Patent infringement suits following Paragraph IV challenge: Abbott Laboratories et al. v. Watson Laboratories, Inc.-Florida et al.; and Abbott Laboratories et al. v. Mylan Pharmaceuticals Inc. et al. (Patent Docs) (GenericsWeb)

Valcyte (Valgancyclovir) – India: Roche loses Valcyte case (Spicy IP) (Generic Pharmaceuticals and IP)

Vanos (Fluocinonide) – US: Patent infringement complaint in response to Para IV certification: Medicis Pharmaceutical Corp. v. Taro Pharmaceutical USA Inc. et al (Patent Docs)

Viagra (Sildenafil) – Brazil patents to expire 1 year early? – Supreme Court of Justice decision on Viagra patent (IPKat) (IP tango)

 

 

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: